JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boast, C. A.
Right arrow Articles by Liebman, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boast, C. A.
Right arrow Articles by Liebman, J. M.

Behavioral tolerance and sensitization to CGS 19755, a competitive N- methyl-D-aspartate receptor antagonist

CA Boast, G Pastor, SC Gerhardt, NR Hall and JM Liebman

Research Department, CIBA-GEIGY Corporation, Summit, New Jersey.

Competitive N-methyl-D-aspartate (NMDA) receptor antagonists, including CGS 19755, have the ability to antagonize NMDA-induced convulsions, to cause ataxia and, at high doses, to increase spontaneous locomotor activity. It was of interest to determine whether or not repeated treatment with CGS 19755 would induce tolerance to some or all of these effects. CGS 19755 was administered to mice twice daily for 14 days at 54 mg/kg i.p. per injection. One day after the last repeated injection, mice were challenged with vehicle or one of several doses of CGS 19755 (10, 30, 54 and 100 mg/kg) and were tested for evidence of motor impairment (using righting reflex and traction tests), for spontaneous locomotor activity and for the threshold dose of NMDA required to induce convulsions. When challenged with CGS 19755, mice that had previously received only vehicle showed reduced motor activity in response to doses of 54 and 100 mg/kg. In contrast, mice that had received the repeated treatment regimen of CGS 19755 increased motor activity in response to challenge doses of 30 and 54 mg/kg. These effects resembled those reported previously by some investigators for phencyclidine. However, repeated treatment with CGS 19755 induced only slight tolerance to the ability of this drug to cause ataxia. In mice treated repeatedly with CGS 19755, the threshold dose of NMDA to induce convulsions did not differ significantly from that in mice treated repeatedly with vehicle, indicating no demonstrable tolerance to the apparent anticonvulsant effects of CGS 19755 over this time period.(ABSTRACT TRUNCATED AT 250 WORDS)

Volume 247, Issue 2, pp. 556-561, 11/01/1988
Copyright © 1988 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
T. Inada, T. Asai, M. Yamada, and K. Shingu
Propofol and Midazolam Inhibit Gastric Emptying and Gastrointestinal Transit in Mice
Anesth. Analg., October 1, 2004; 99(4): 1102 - 1106.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
A. B. Petrenko, T. Yamakura, N. Fujiwara, A. R. Askalany, H. Baba, and K. Sakimura
Reduced Sensitivity to Ketamine and Pentobarbital in Mice Lacking the N-Methyl-D-Aspartate Receptor GluR{epsilon}1 Subunit
Anesth. Analg., October 1, 2004; 99(4): 1136 - 1140.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
M. Irifune, T. Sato, Y. Kamata, T. Nishikawa, T. Dohi, and M. Kawahara
Evidence for GABAA Receptor Agonistic Properties of Ketamine: Convulsive and Anesthetic Behavioral Models in Mice
Anesth. Analg., July 1, 2000; 91(1): 230 - 236.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1988 by the American Society for Pharmacology and Experimental Therapeutics.